Ben Mahaney, Editor

About the Author Ben Mahaney, Editor

Smarter Analyst Site Personnel

Two Biotech Stocks Analysts Are Talking About: Immunomedics, Inc. (IMMU), Ocular Therapeutix Inc (OCUL)

Immunomedics, Inc. Immunomedics, Inc. (NASDAQ:IMMU) shares jumped nearly 26% in Friday’s trading session, following the …

Read more

United States Oil Fund LP (ETF) (USO): Mr. Sandman, the Unsung Hero Against OPEC Oil War

The late-2014, Saudi-initiated oil-price war may have taken the ‘boom’ out of the US shale …

Read more

The ECB’s Corporate Bond Purchase Programme Takes Shape

By Marcello Minenna, With the awaited decision of August 4, even the Bank of England …

Read more

The Biotech Round-Up: Valeant Pharmaceuticals Intl Inc, Inovio Pharmaceuticals Inc, Synergy Pharmaceuticals Inc, Ionis Pharmaceuticals Inc

Valeant Pharmaceuticals Intl Inc Analyst Ram Selvaraju of Rodman & Renshaw was out with a research …

Read more

Tuesday’s Insights: GoPro Inc (GPRO), SolarCity Corp (SCTY), Alibaba Group Holding Ltd (BABA)

U.S. stocks took their biggest loss in almost a month on Tuesday as weak U.S. economic …

Read more

Monday Morning’s Insights: Celldex Therapeutics, Inc. (CLDX), Linn Energy LLC (LINE), LinnCo LLC (LNCO)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shareholders are having a rough morning as the company’s shares are collapsing, down 51% …

Read more

Stock Market Top-Callers Are Missing One Key Ingredient

Ding Dong! The Wicked Bull Is Dead If you follow the markets, you may have …

Read more

UPDATE: J.P. Morgan Reiterates Overweight on Vertex Pharmaceuticals Incorporated Following Positive FDA AdCom Recommendation

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are up 8% in after-market trading after the FDA’s advisory committee panel recommended …

Read more

J.P. Morgan Remains On The Sidelines With Ariad Pharmaceuticals, Inc. Following 1Q:15 Update

J.P. Morgan’s healthcare analyst Cory Kasimov came out with his views on Ariad Pharmaceuticals, Inc. …

Read more

Before The Bell: Needham Reiterates Buy On Gilead Sciences, Inc. Due To Strong 1Q15 HCV Sales

Gilead Sciences, Inc. (NASDAQ:GILD) has been reiterated as a Buy at Needham by research analyst Alan Carr in …

Read more